Related Experiment Videos
Cytotoxicity of gallium nitrate in vitro using bladder cancer cells
1Department of Urology, National Defense Medical College, Tokorozawa, Japan.
Background:
Gallium nitrate has been used systemically for some malignancies in clinical trials. Because bladder cancer has many transferrin (Tf) receptors and gallium has been reported to bind avidly with Tf receptors, gallium cytotoxicity and the possibility of intravesical instillation therapy with gallium nitrate were studied in vitro.
Methods:
The bladder cancer cell lines J82, 639V, VMCuB1, SCaBER, and 5637 were used. The amount of Tf receptor was checked by a rosette assay. As a cytotoxicity assay, two experimental models were tested using two or 72 hours of exposure to gallium solution. A gallium release study using 67Ga was done to investigate the movement of incorporated gallium.
Results:
J82 had the most and SCaBER had the least Tf receptors. For 72 hours of exposure at gallium concentrations above 250 mumol/L, the inhibitory effect was a function of gallium concentration, and 100% cytotoxicity occurred at 2 mmol/L. At lower concentrations of gallium, the effect was related to the amount of Tf and the level of Tf receptor expression of the cells. With two hours of exposure, which was assumed to be a model of intravesical therapy, the inhibitory effect increased in proportion to gallium concentration and the frequency of treatment. Twenty mmol/L gallium effectively inhibited the growth in two hours of exposure.
Conclusions:
Intravesically administered gallium might be an effective therapy for bladder cancer, because its cytotoxicity is determined not by the amount of Tf receptor but by the gallium concentration and the duration of gallium exposure.
Insights
Intravesical gallium nitrate shows promise for bladder cancer treatment. Its effectiveness depends on gallium concentration and exposure duration, not transferrin receptor levels, suggesting a potential new therapy.
Area of Science:
- Oncology
- Urology
- Biochemistry
Background:
- Gallium nitrate has been investigated for systemic cancer therapy.
- Bladder cancer cells exhibit numerous transferrin (Tf) receptors, which bind gallium.
- This study explored gallium's cytotoxicity and potential for intravesical instillation in bladder cancer.
Purpose of the Study:
- To evaluate the in vitro cytotoxicity of gallium nitrate against bladder cancer cell lines.
- To assess the feasibility of intravesical gallium nitrate therapy for bladder cancer.
Main Methods:
- Utilized five human bladder cancer cell lines (J82, 639V, VMCuB1, SCaBER, 5637).
- Assessed transferrin receptor expression using a rosette assay.
- Conducted cytotoxicity assays with 2-hour and 72-hour gallium exposure.
- Investigated gallium incorporation and movement using 67Ga release studies.
Main Results:
- Gallium nitrate demonstrated dose-dependent cytotoxicity, achieving 100% cell death at 2 mmol/L after 72 hours.
- Short-term (2-hour) exposure showed increased inhibition with higher gallium concentrations and treatment frequency.
- Cytotoxicity was primarily influenced by gallium concentration and exposure time, rather than transferrin receptor levels.
Conclusions:
- Intravesical gallium nitrate may be an effective treatment for bladder cancer.
- Therapeutic efficacy is linked to gallium concentration and exposure duration.
- This suggests a potential new intravesical therapy for bladder cancer independent of transferrin receptor expression.